Cardiol Therapeutics hits halfway mark in pivotal heart inflammation trial
Cardiol Therapeutics (NASDAQ:CRDL) announced Tuesday that it has surpassed 50% patient enrollment in its pivotal Phase III MAVERIC trial, a major step toward bringing the first non-immunosuppressive oral therapy to patients suffering from recurrent pericarditis.








-640x358.jpg&w=3840&q=75)
-640x358.jpg&w=3840&q=75)
